{
    "nctId": "NCT00641303",
    "briefTitle": "Acupuncture in Reducing Muscle and Bone Symptoms in Women Receiving Letrozole, Exemestane, or Anastrozole for Stage 0, Stage I, Stage II, or Stage III Breast Cancer",
    "officialTitle": "A Multi-Center Randomized Controlled Double Blind Trial Assessing the Effect of Acupuncture in Reducing Musculoskeletal Symptoms in Breast Cancer Patients Taking Aromatase Inhibitors",
    "overallStatus": "COMPLETED",
    "conditions": "Anxiety Disorder, Breast Cancer, Depression, Fatigue, Hot Flashes, Pain, Sleep Disorders",
    "studyType": "INTERVENTIONAL",
    "phase": "NA",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "SUPPORTIVE_CARE",
    "enrollmentCount": 51,
    "primaryOutcomeMeasure": "Health Assessment Questionnaire Disability Index (HAQ-DI) score",
    "eligibilityCriteria": "DISEASE CHARACTERISTICS:\n\n* Histologically confirmed invasive carcinoma of the breast\n\n  * Stage 0-III disease\n* Estrogen receptor- and/or progesterone receptor-positive by immunohistochemical staining\n* Must be receiving a standard dose of aromatase inhibitor (AI) therapy (i.e., letrozole 2.5 mg once daily, exemestane 25 mg once daily, or anastrozole 1 mg once daily)\n\n  * AI therapy has been ongoing for \u2265 1 month and treatment is expected to continue\n* AI-associated musculoskeletal symptoms, defined as \u2265 1 of the following:\n\n  * Physician-confirmed AI-associated musculoskeletal symptoms\n  * Patients concurrently enrolled on the clinical trial, \"A Multi-Center Randomized Clinical Trial Correlating the Effects of 24 Months of Exemestane or Letrozole on Surrogate Markers of Response with Aromatase Polymorphism,\" and who have met the referral criteria for a rheumatological evaluation\n* No known metastatic (stage IV) breast cancer\n\nPATIENT CHARACTERISTICS:\n\n* ECOG performance status 0-2\n* Female\n* Menopausal status not specified\n\nPRIOR CONCURRENT THERAPY:\n\n* No prior acupuncture within past 12 months.\n* No other concurrent systemic therapy (i.e., chemotherapy, biologic therapy, or radiotherapy) unless approval is given by the Protocol Chair",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}